1 not yet recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Manuel Coelho da Rocha: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tailored Vs. Empirical Helicobacter Pylori Infection Treatment Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Manuel Coelho da Rocha | 160 | 2025-09-01 | 2024-12-20 |
Amoxicillin (1) · Clarithromycin (1) · Levofloxacin (1) · Mutation (1) · WW Domain-Containing Oxidoreductase (1)
Portugal (1)